Home > News
Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval
The Food and Drug Administration (FDA) has expanded the approved uses for a blood test, known as a liquid biopsy, that can help doctors pick the best treatments for some people with cancer. The test identifies cancer-related genetic changes in DNA from tumor cells that have been released into the blood.

Nanoparticle Trains Immune Cells to Attack Cancer
Cancer researchers are exploring all kinds of new and creative approaches to immunotherapy, treatments that help the immune system fight cancer. The latest involves nanoparticles that trains immune cells to attack cancer.

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers


FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation


Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial


FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion


FGFR2 fusions appear to be much less frequent in tumours arising in the context of chronic liver fluke infection, the most common aetiology in SE Asia.


Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update(2)


Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update


Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers


Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]


Oncodna logo - wideToggle main menu visibility ENDOMETRIAL CANCER: Data from SGO 2020 indicate survival benefit for the addition of trastuzumab to standard chemo for those with advanced ERBB2-expressing (HER2+) disease (OS 24.4 versus 29.6 months) April 27, 2020 SCIENTIFIC Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): Updated survival analysis